Kirsi J Granberg
Overview
Explore the profile of Kirsi J Granberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kukkonen K, Taavitsainen S, Huhtala L, Uusi-Makela J, Granberg K, Nykter M, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34283056
The dysregulation of chromatin and epigenetics has been defined as the overarching cancer hallmark. By disrupting transcriptional regulation in normal cells and mediating tumor progression by promoting cancer cell plasticity,...
2.
Filppu P, Tanjore Ramanathan J, Granberg K, Gucciardo E, Haapasalo H, Lehti K, et al.
JCI Insight
. 2021 May;
6(9).
PMID: 33986188
Glioma stem cells (GSCs) drive propagation and therapeutic resistance of glioblastomas, the most aggressive diffuse brain tumors. However, the molecular mechanisms that maintain the stemness and promote therapy resistance remain...
3.
Rajamaki K, Taira A, Katainen R, Valimaki N, Kuosmanen A, Plaketti R, et al.
Gastroenterology
. 2021 Apr;
161(2):592-607.
PMID: 33930428
Background & Aims: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder associated with an elevated risk of colorectal cancer (CRC). IBD-associated CRC (IBD-CRC) may represent a distinct pathway...
4.
Granberg K, Raita A, Lehtinen B, Tiihonen A, Kesseli J, Annala M, et al.
Histol Histopathol
. 2019 Oct;
35(7):673-680.
PMID: 31660579
Deregulation of fibroblast growth factor receptor (FGFR) signaling is tightly associated with numerous human malignancies, including cancer. Indeed, FGFR inhibitors are being tested as anti-tumor drugs in clinical trials. Among...
5.
Polonen P, Mehtonen J, Lin J, Liuksiala T, Hayrynen S, Teppo S, et al.
Cancer Res
. 2019 Apr;
79(10):2466-2479.
PMID: 30940663
Large collections of genome-wide data can facilitate the characterization of disease states and subtypes, permitting pan-cancer analysis of molecular phenotypes and evaluation of disease context for new therapeutic approaches. We...
6.
Lehtipuro S, Nykter M, Granberg K
Oncotarget
. 2019 Mar;
10(9):920-921.
PMID: 30847018
No abstract available.
7.
Luoto S, Hermelo I, Vuorinen E, Hannus P, Kesseli J, Nykter M, et al.
Cancer Res
. 2018 Jun;
78(19):5574-5585.
PMID: 29921698
The immunosuppressive microenvironment in glioblastoma (GBM) prevents an efficient antitumoral immune response and enables tumor formation and growth. Although an understanding of the nature of immunosuppression is still largely lacking,...
8.
Nordfors K, Haapasalo J, Afyounian E, Tuominen J, Annala M, Hayrynen S, et al.
Cold Spring Harb Mol Case Stud
. 2018 Jun;
4(3).
PMID: 29858379
No abstract available.
9.
Nordfors K, Haapasalo J, Afyounian E, Tuominen J, Annala M, Hayrynen S, et al.
Cold Spring Harb Mol Case Stud
. 2018 Apr;
4(2).
PMID: 29602769
Brain tumors typically arise sporadically and do not affect several family members simultaneously. In the present study, we describe clinical and genetic data from two patients, a mother and her...
10.
Haapasalo J, Nordfors K, Granberg K, Kivioja T, Nykter M, Haapasalo H, et al.
Histol Histopathol
. 2018 Feb;
33(8):791-801.
PMID: 29441509
Nuclear factor erythroid 2-related factor 2 (NRF2), DJ1 and sulfiredoxin 1 (SRXN1) are transcription factors which protect cells from the oxidative damage caused by reactive oxygen species and, on the...